CA3058802A1 - Mineral coated microparticles for sustained delivery of biologically active molecules - Google Patents
Mineral coated microparticles for sustained delivery of biologically active molecules Download PDFInfo
- Publication number
- CA3058802A1 CA3058802A1 CA3058802A CA3058802A CA3058802A1 CA 3058802 A1 CA3058802 A1 CA 3058802A1 CA 3058802 A CA3058802 A CA 3058802A CA 3058802 A CA3058802 A CA 3058802A CA 3058802 A1 CA3058802 A1 CA 3058802A1
- Authority
- CA
- Canada
- Prior art keywords
- mineral
- active agent
- antagonist
- coating
- mineral coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480710P | 2017-04-03 | 2017-04-03 | |
| US62/480,710 | 2017-04-03 | ||
| PCT/US2018/025913 WO2018187344A1 (en) | 2017-04-03 | 2018-04-03 | Mineral coated microparticles for sustained delivery of biologically active molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3058802A1 true CA3058802A1 (en) | 2018-10-11 |
Family
ID=63712804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3058802A Pending CA3058802A1 (en) | 2017-04-03 | 2018-04-03 | Mineral coated microparticles for sustained delivery of biologically active molecules |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12465654B2 (enExample) |
| EP (1) | EP3606512A4 (enExample) |
| JP (1) | JP7170031B2 (enExample) |
| KR (1) | KR20190130643A (enExample) |
| CN (1) | CN110691588A (enExample) |
| AU (1) | AU2018249816B2 (enExample) |
| BR (1) | BR112019020373A2 (enExample) |
| CA (1) | CA3058802A1 (enExample) |
| IL (1) | IL269607A (enExample) |
| WO (1) | WO2018187344A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3606512A4 (en) | 2017-04-03 | 2021-01-13 | Wisconsin Alumni Research Foundation | MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES |
| WO2022051247A1 (en) * | 2020-09-01 | 2022-03-10 | Dianomi Therapeutics, Inc. | Methods for treating or preventing inflammatory events |
| DE102020129648A1 (de) * | 2020-11-10 | 2022-05-12 | Leopold MTX GmbH | Pharmazeutische zusammensetzung |
| CN114917364A (zh) * | 2022-05-12 | 2022-08-19 | 云南大学附属医院 | 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法 |
| WO2024102801A2 (en) * | 2022-11-09 | 2024-05-16 | Wisconsin Alumni Research Foundation | Mineral-coated iron oxide microparticles and use of same including use for immunomodulation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| JP2003212756A (ja) * | 2002-01-21 | 2003-07-30 | Olympus Optical Co Ltd | 薬剤徐放剤 |
| CA2568352C (en) * | 2004-06-04 | 2011-09-13 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| US7655758B2 (en) * | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| AU2006290870B2 (en) * | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| JPWO2008041704A1 (ja) | 2006-10-02 | 2010-02-04 | 独立行政法人物質・材料研究機構 | 徐放性製剤 |
| US20100143439A1 (en) * | 2007-04-16 | 2010-06-10 | University Of Toledo | Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor |
| US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| US20090111763A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable polymeric particles for bone augmentation and methods of preparing and using the same |
| CN105688276A (zh) | 2008-02-29 | 2016-06-22 | 史密夫和内修有限公司 | 用于生物医学应用的梯度涂层 |
| US20100015049A1 (en) * | 2008-07-16 | 2010-01-21 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| JP2012503673A (ja) * | 2008-09-25 | 2012-02-09 | ティッシュ リジェネレーション システムズ インコーポレイテッド | ミネラルコーティングされたマイクロスフェア |
| US20160017368A1 (en) | 2013-02-19 | 2016-01-21 | Wisconsin Alumni Research Foundation | Inorganic coatings for the enhancement of chemical transfection |
| WO2016141242A1 (en) | 2015-03-03 | 2016-09-09 | Tissue Regeneration Systems, Inc. | Coating scaffolds |
| US10780054B2 (en) | 2015-04-17 | 2020-09-22 | Curevac Real Estate Gmbh | Lyophilization of RNA |
| EP3606512A4 (en) | 2017-04-03 | 2021-01-13 | Wisconsin Alumni Research Foundation | MINERAL COATED MICROPARTICLES INTENDED FOR THE PROLONGED DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES |
| JP2020526515A (ja) | 2017-07-05 | 2020-08-31 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーションWisconsin Alumni Research Foundation | 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子 |
| US11628227B2 (en) | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
| EP3556728A1 (en) | 2018-04-16 | 2019-10-23 | Croda Denmark A/S | Organically modified mineral micro-particles, methods of preparing the same and uses thereof |
| US20190358344A1 (en) | 2018-05-23 | 2019-11-28 | Dianomi Therapeutics, Inc. | Mineral coated microparticles for sustained delivery of steroids |
| WO2023086816A1 (en) | 2021-11-09 | 2023-05-19 | Wisconsin Alumni Research Foundation | Mineral-coated substrates for stabilization of rna-based therapeutic compositions |
-
2018
- 2018-04-03 EP EP18780858.9A patent/EP3606512A4/en active Pending
- 2018-04-03 AU AU2018249816A patent/AU2018249816B2/en active Active
- 2018-04-03 BR BR112019020373-7A patent/BR112019020373A2/pt active Search and Examination
- 2018-04-03 KR KR1020197032235A patent/KR20190130643A/ko not_active Ceased
- 2018-04-03 JP JP2020502549A patent/JP7170031B2/ja active Active
- 2018-04-03 US US16/500,017 patent/US12465654B2/en active Active
- 2018-04-03 CA CA3058802A patent/CA3058802A1/en active Pending
- 2018-04-03 WO PCT/US2018/025913 patent/WO2018187344A1/en not_active Ceased
- 2018-04-03 CN CN201880036493.0A patent/CN110691588A/zh active Pending
-
2019
- 2019-09-24 IL IL26960719A patent/IL269607A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL269607A (en) | 2019-11-28 |
| JP2020513033A (ja) | 2020-04-30 |
| WO2018187344A1 (en) | 2018-10-11 |
| EP3606512A4 (en) | 2021-01-13 |
| EP3606512A1 (en) | 2020-02-12 |
| BR112019020373A2 (pt) | 2020-04-28 |
| KR20190130643A (ko) | 2019-11-22 |
| AU2018249816A1 (en) | 2019-10-17 |
| US12465654B2 (en) | 2025-11-11 |
| US20200164087A1 (en) | 2020-05-28 |
| CN110691588A (zh) | 2020-01-14 |
| AU2018249816B2 (en) | 2025-04-17 |
| JP7170031B2 (ja) | 2022-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12465654B2 (en) | Mineral coated microparticles for sustained delivery of biologically active molecules | |
| JP2020189878A (ja) | 抗炎症剤としてのprg4の使用 | |
| AU2014346051B2 (en) | Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis | |
| Chi et al. | Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments | |
| AU2015292582A1 (en) | Collagen IV replacement | |
| EP2941243A1 (en) | Surface binding of nanoparticle based drug delivery to tissue | |
| JP2022081677A (ja) | 線維症の処置のためのインターフェロン-ラムダの医学的使用 | |
| WO2019213686A1 (en) | Therapeutic compositions and uses therefor | |
| JP2024520202A (ja) | Il-23に対する抗体及びtnfアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患を治療する方法 | |
| JP2024526919A (ja) | 結晶及び非結晶に関連付けられた急性炎症性関節炎の処置において使用する為の、コルヒチンを含有する関節内注射の為の剤形 | |
| US12371501B2 (en) | Extended local release of anti-CSFR1 antibodies | |
| HK40014557A (en) | Mineral coated microparticles for sustained delivery of biologically active molecules | |
| WO2022051247A1 (en) | Methods for treating or preventing inflammatory events | |
| JP2024516563A (ja) | 泌尿器系障害の処置のための製剤及び方法 | |
| Xiang et al. | Recent Advances in Biomimetic Drug Delivery for Rheumatoid Arthritis Treatment | |
| WO2023027132A1 (ja) | 骨代謝細胞調節剤及びその利用 | |
| WO2022146925A1 (en) | Extended local release of antibodies | |
| Egashira et al. | Novel biological strategies for treatment of wear | |
| Torres et al. | Listeria Infection. |